Tumoral Uptake in SCID Mice Injected With XG-1 Myeloma Cells
| Site of Tumor Injection . | No. of Mice Developing Tumors or With Detectable Tumoral Infiltration After 200 d of Myeloma Cell Implantation . |
|---|---|
| Blood | 0/5 |
| Spleen | 0/5 |
| Peritoneum | 0/5 |
| Peritoneum + matrigel (delay of tumor detection) | 15/15 (4-5 wks) |
| Peritoneum + matrigel with no anti-gp130 MoAbs (delay of tumor detection) | 5/5 (20-24 wks) |
| Site of Tumor Injection . | No. of Mice Developing Tumors or With Detectable Tumoral Infiltration After 200 d of Myeloma Cell Implantation . |
|---|---|
| Blood | 0/5 |
| Spleen | 0/5 |
| Peritoneum | 0/5 |
| Peritoneum + matrigel (delay of tumor detection) | 15/15 (4-5 wks) |
| Peritoneum + matrigel with no anti-gp130 MoAbs (delay of tumor detection) | 5/5 (20-24 wks) |
XG-1 myeloma cells (50 × 106) were injected either IV, IS, or IP in SCID mice. These mice were injected IP 2 days before with 100 μg of B-S12 + B-P8 anti-gp130 MoAbs. Then, 50 μg of B-S12 + B-P8 anti-gp130 MoAbs were injected IP every fortnight. In one group, 50 × 106 myeloma cells were imbedded in 150 μL of soft matrigel together with 3 μg of the anti-gp130 MoAb mixture (1.5 μg each), and the gel was implanted surgically IP. Mice either developed tumors (IP + matrigel group) or were killed at 200 days to look for human myeloma cells in the bone marrow, spleen, blood, or liver.